The Investment Case For AstraZeneca plc

AstraZeneca plc (LON:AZN) is a biotech play that pays a dividend.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

“Hope will triumph over adversity.” That may be harsh, but it sums up the investment case for AstraZeneca (LSE: AZN) (NYSE: AZN.US), or at least its burgeoning share price, which is at its highest for over a decade: that at a time of secular decline in Astra’s sales and profits.

The adversity is Astra’s well-known patent cliff. As proprietary drugs have lost patent protection sales have declined, dropping 20% in 2012 and an anticipated 10% or so in 2013. It’s not over yet, with three key drugs responsible for 45% of sales coming off-patent between 2014 and 2016.

The hope is that Astra can rebuild its pipeline of drugs with new discoveries, helped along by a smattering of acquisitions. By and large, investors’ fate is in the hands of Astra’s scientists.

Biotech

Pascal Soriot, CEO since 2012, has eschewed the diversification strategy of sector peer GlaxoSmithKline in favour of concentrating on research and development of new drugs. That makes the company essentially a biotech play — quite different in character from the traditional notion of pharmaceuticals as defensive stocks. But there are two big differences between an investment in Astra and one in a more speculative biotech company.

First, Astra is large and diversified, with multiple drug therapies under development. The company is focused on three therapeutic areas: oncology; cardiovascular and metabolic disease; and respiratory, inflammation and autoimmune diseases. It’s doing well bringing new drugs through trials, with 11 treatments now in the critical ‘Phase III’ stage, nearly double the number last year.

That perhaps owes something to M. Soriot’s new, streamlined structure — cutting both costs and bureaucracy. He has also spent $7bn on acquiring new therapies, despite rejecting a ‘big-bang’ acquisition strategy.

Dividend

The second big difference is that Astra pays a dividend — and a fat one at that, currently yielding 4.4%. The dividend is covered, too. Management has given itself the wriggle-room of two-times cover ‘over the investment cycle’, whatever that may be. Astra’s strong balance sheet, with net gearing of just 11%, provides a financial safety net.

The momentum behind Astra’s shares could continue, with the company now saying it expects to return to growth sooner than analysts’ expectations. It expects 2017 revenues to be in line with 2013’s, whereas previously 2018 was the target date. That could lead to the oddest of broker upgrade cycles: pencilling in smaller-than-previously-forecast falls in sales.

Astra’s discount to GlaxoSmithKline has narrowed. Investors will only know if that is merited if and when Astra’s new drugs come to market.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

 > Tony owns shares in AstraZeneca and GlaxoSmithKline. The Motley Fool has recommended shares in GlaxoSmithKline.

 

More on Investing Articles

Investing Articles

Surely, the Rolls-Royce share price can’t go any higher in 2025?

The Rolls-Royce share price was the best performer on the FTSE 100 in 2023 and so far in 2024. Dr…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

Here’s how an investor could start buying shares with £100 in January

Our writer explains some of the things he thinks investors on a limited budget should consider before they start buying…

Read more »

Investing Articles

Forget FTSE 100 airlines! I think shares in this company offer better value to consider

Stephen Wright thinks value investors looking for shares to buy should include aircraft leasing company Aercap. But is now the…

Read more »

Investing Articles

Are Rolls-Royce shares undervalued heading into 2025?

As the new year approaches, Rolls-Royce shares are the top holding of a US fund recommended by Warren Buffett. But…

Read more »

Investing Articles

£20k in a high-interest savings account? It could be earning more passive income in stocks

Millions of us want a passive income, but a high-interest savings account might not be the best way to do…

Read more »

Investing Articles

3 tried and tested ways to earn passive income in 2025

Our writer examines the latest market trends and economic forecasts to uncover three great ways to earn passive income in…

Read more »

Investing Articles

Here’s what £10k invested in the FTSE 100 at the start of 2024 would be worth today

Last week's dip gives the wrong impression of the FTSE 100, which has had a pretty solid year once dividends…

Read more »

Investing Articles

UK REITs: a once-in-a-decade passive income opportunity?

As dividend yields hit 10-year highs, Stephen Wright thinks real estate investment trusts could be a great place to consider…

Read more »